1. Home
  2. FTRE vs NVAX Comparison

FTRE vs NVAX Comparison

Compare FTRE & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$15.82

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.13

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTRE
NVAX
Founded
1996
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
FTRE
NVAX
Price
$15.82
$8.13
Analyst Decision
Buy
Hold
Analyst Count
9
8
Target Price
$15.56
$9.75
AVG Volume (30 Days)
1.4M
4.2M
Earning Date
03-02-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.07
Revenue
$2,759,900,000.00
$1,064,651,000.00
Revenue This Year
$3.17
$58.91
Revenue Next Year
$0.07
N/A
P/E Ratio
N/A
$3.87
Revenue Growth
1.88
20.27
52 Week Low
$3.97
$5.01
52 Week High
$19.00
$10.65

Technical Indicators

Market Signals
Indicator
FTRE
NVAX
Relative Strength Index (RSI) 46.20 62.15
Support Level $16.98 $7.73
Resistance Level $17.24 $8.81
Average True Range (ATR) 1.11 0.45
MACD -0.36 0.10
Stochastic Oscillator 13.64 69.30

Price Performance

Historical Comparison
FTRE
NVAX

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: